Category Archives: Transhuman News

The most common symptom of atopic dermatitis is itching, which can be severe. Other common symptoms include:

The symptoms can flare in multiple areas of the body at the same time and can appear in the same locations and in new locations. The appearance and location of the rash vary depending on age; however, the rash can appear anywhere on the body.

During infancy and up to 2 years of age, it is most common for a red rash, which may ooze when scratched, to appear on the:

Some parents worry that the infant has atopic dermatitis in the diaper area; however, the condition rarely appears in this area.

During childhood, usually 2 years of age to puberty, it is most common for a red thickened rash, which may ooze or bleed when scratched, to appear on the:

During the teenage and adult years, it is most common for a red to dark brown scaly rash, which may bleed and crust when scratched, to appear on the:

Other common skin features of atopic dermatitis include:

In addition, people with atopic dermatitis often have other conditions, such as:

Researchers continue to study why having atopic dermatitis as a child can lead to the development of asthma and hay fever later in life.

Complications of atopic dermatitis can happen. They include:

See the rest here:
Atopic Dermatitis Treatment, Symptoms & Causes | NIAMS

We include products we think are useful for our readers. If you buy through links on this page, we may earn a small commission. Heres our process.

Eczema or atopic dermatitis is a condition that causes a person to develop patches of dry, itchy skin on their body. It often develops as a result of inflammation in the body, so eating foods that do not cause inflammation may help reduce symptoms.

While no cure exists, over-the-counter creams and medications that can help to reduce inflammation are available. Sometimes, a doctor may recommend avoiding foods known to make eczema worse.

Some foods may trigger the release of T cells that cause inflammation, as well as immunoglobulin-E or IgE, which is an antibody that the body produces in response to a threat. Foods that contribute to inflammation include nuts, milk, and wheat.

For people with eczema, eating certain foods can trigger the body to release immune system compounds that cause inflammation, which, in turn, contributes to an eczema flare-up. An anti-eczema diet is similar to an anti-inflammatory diet.

Examples of anti-inflammatory foods include:

Eating more of these foods and cutting down on any trigger foods could help to reduce eczema flare-ups.

Food-sensitive eczema reactions will typically occur about 6 to 24 hours after a person eats a particular food. Sometimes, these reactions may be delayed even longer.

To determine what foods may be causing the reaction, a doctor will often recommend an elimination diet. This diet involves avoiding some of the most common foods known to cause eczema.

Before eliminating any foods, a person will need to slowly add each food type into their diet and monitor their eczema for 4 to 6 weeks to determine if they are sensitive to any particular food.

If a persons symptoms get worse after adding a particular food to the diet, they may wish to consider avoiding it in the future. If a persons symptoms do not improve when eliminating a food, they probably do not need to remove it from their diet.

Some common foods that may trigger an eczema flare-up and could be removed from a diet include:

A doctor may also recommend allergy testing. Even if a person is not allergic to a particular food, they may have sensitivity to it and could experience skin symptoms after repeat exposure. Doctors call this reaction food responsive eczema.

People with dyshidrotic eczema, which typically affects the hands and feet, may experience benefits from eating foods that do not contain nickel. Nickel is found in trace amounts in the soil and can, therefore, be present in foods.

Foods that are high in nickel include:

Some people with eczema also have oral allergy syndrome or sensitivity to birch pollen. This means they may have reactions to other foods, including:

People with eczema are more prone to oral allergy syndrome and should speak to their doctor if they have a pollen allergy or experience mild allergic reactions to the above foods.

Research has shown that taking probiotic supplements may reduce the symptoms of eczema. More studies are needed, however, to confirm the effectiveness and dosage required.

Probiotics are available in a variety of supplements, such as the selection available here. If a person is not sure which probiotics to buy, they may find the online reviews helpful and can also talk to their doctor.

Probiotics are also naturally present in many foods. Probiotic foods include:

Other supplements that have been studied include fish oil and Chinese herbal preparations; neither of which made a significant difference in eczema symptoms.

While a persons diet is not always a trigger for eczema, some people may find that their symptoms do get better when they make dietary changes.

Making these changes and monitoring the results can help a person determine whether changing their diet can help them better manage their condition.

If a person does eliminate a large food group, such as wheat-containing products, they may wish to talk to their doctor about supplements to ensure they are not missing out on any essential vitamins and minerals.

Read more:
Eczema diet tips: Foods to eat and avoid

On Jan. 14, AbbVie's (NYSE:ABBV) Rinvoq received approval from the U.S. Food and Drug Administration (FDA) to treat adults and children at least 12 years old with moderate-to-severe atopic dermatitis (eczema) whose condition didn't respond to other medicines.

What led the FDA to approve Rinvoq for its third indication? And how much of a boost could this be for AbbVie's sales? Let's dig into the phase 3 clinical trial results and U.S. moderate-to-severe eczema market to find the answers to these two questions.

Image source: Getty Images.

According to Healthline, eczema is a chronic skin condition often expressed by patches of dry, inflamed, and itchy skin. It's thought that the disease is caused by excessive production of immune system cells that lead to inflammation. Eczema typically begins in early childhood and flares up from time to time.

Common first-line treatments for the condition include antihistamines and topical corticosteroids (TCS). Unfortunately, a majority of patients with moderate-to-severe eczema (55%) cannot control their eczema with their current treatment regimen. This can result in sleep issues and weigh on a patient's quality of life, which is why there's demand for more treatments for the disease.

Fortunately, more treatment options are making their way to the market. One of those treatments is Rinvoq, which was approved last August in the European Union to treat moderate-to-severe eczema.What data is there to support the approval in the EU and most recently in the U.S.?

Rinvoq funded a randomized clinical trial of 901 moderate-to-severe eczema patients. These patients were blindly assigned to either receive 15 milligrams of Rinvoq once daily with TCS, 30 milligrams of Rinvoq each day combined with TCS, or a placebo pill and TCS. The patients were followed over the course of a 16-week period. The more pronounced the reduction in the Eczema Area and Severity Index (EASI), the more effective a treatment was for eczema patients. The EASI is a clinical scale that measures eczema's severity and surface area. A 75% or greater improvement in the EASI is called EASI75, which is the best indication of whether a treatment is effective enough to be approved by regulatory agencies.

Patients taking TCS and the lower dose of Rinvoq were found to have reached at least 75% clearer skin, or EASI75, at a 65% rate at week 16, which was much higher than the 26% rate for the TCS and placebo group at week 16. Even more striking, 77% of patients receiving the higher dose of Rinvoq achieved EASI75 at week 16.

Rinvoq could be a powerful treatment for many patients with eczema. So, what could this mean for pharma stock AbbVie?

First, it's estimated that there are 6.6 million adults in the U.S. with moderate-to-severe eczema. For the sake of conservatism and sparse data being available, I won't include the population of U.S. adolescents with the disease.

Second, although 55% of moderate-to-severe eczema patients aren't satisfied with their treatment plan, I'll assume that approximately 20% of the patient pool could start Cibinqo.This works out to 1.3 million potential patients.

Third, Cibinqo has the benefit of being a pill, which helps patients avoid having to go into clinics and hospitals for injections to treat their condition. On the other hand, the convenience of Cibinqo could be at least partially offset by the fact that the drug is a Janus kinase inhibitor. Due to the increased risk of serious adverse events like blood clots, cancer, and major heart-related issues, the FDA could end up restricting patients to just the lower dose of Cibinqo for safety reasons.

Considering all of these factors, I believe that the drug could capture 6% of the market, or 79,000 patients.

Rinvoq has an annual list price of $68,000. Adjusting for patient assistance programs and negotiations from health insurers, I'll use $20,000 as the net annual price per patient. This equates to just under $1.6 billion in annual revenue potential.

Against the $59.8 billion in revenue that analysts are forecasting for AbbVie this year, this would be a nearly 3% boost to the company's overall revenue. An additional $1.6 billion in annual revenue for AbbVie would represent a 30%+ increase in the company's non-Humira immunology segment revenue over the nearly $4.6 billion in combined Skyrizi and Rinvoq revenue for last year.

AbbVie's 8.5% increase in the dividends per share that it will pay out to shareholders in 2022 brings its dividend increase streak to 50 consecutive years -- including its time as part of Abbott Laboratories. This makes the stock a Dividend King.

AbbVie is trading at a forward price-to-earnings (P/E) ratio of 9.8, which is an appealing valuation considering that the stock's earnings are expected to grow 5% annually in the next five years. Investors can scoop up shares of AbbVie and its market-trouncing, steady 4.1% dividend yield on the cheap. That's what makes the stock an attractive option for income investors at the current $140 share price.

This article represents the opinion of the writer, who may disagree with the official recommendation position of a Motley Fool premium advisory service. Were motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

More:
AbbVie Wins Yet Another Approval for This Drug - Motley Fool

[90 Pages Report] Baby Ointment Market Insights 2022 This report contains market size and forecasts of Baby Ointment in United States, including the following market information:

United States Baby Ointment Market Revenue, 2016-2021, 2022-2027, (USD millions)

United States Baby Ointment Market Sales, 2016-2021, 2022-2027, (K Units)

United States top five Baby Ointment companies in 2020 (%)

The global Baby Ointment market size is expected to growth from USD million in 2020 to USD million by 2027; it is expected to grow at a CAGR of % during 2021-2027.

The United States Baby Ointment market was valued at USD million in 2020 and is projected to reach USD million by 2027, at a CAGR of % during the forecast period.

The Research has surveyed the Baby Ointment manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Get a Sample PDF of report https://www.360researchreports.com/enquiry/request-sample/19458710

Leading key players of Baby Ointment Market are

Baby Ointment Market Type Segment Analysis (Market size available for years 2022-2027, Consumption Volume, Average Price, Revenue, Market Share and Trend 2015-2027): Massage Oils, Lotions, Medicinal Creams

Regions that are expected to dominate the Baby Ointment market are North America, Europe, Asia-Pacific, South America, Middle East and Africa and others

If you have any question on this report or if you are looking for any specific Segment, Application, Region or any other custom requirements, then Connect with an expert for customization of Report.

Get a Sample PDF of report https://www.360researchreports.com/enquiry/request-sample/19458710

For More Related Reports Click Here :

Cresylic Acid Market In 2022

Band Saw Blades Market In 2022

Go here to read the rest:
(New Report) Baby Ointment Market In 2022 : The Increasing use in Eczema, Heat Rash, Diaper Rash, Dry Skin, Cuts, Insect Bites is driving the growth...

Eli Lilly has made the difficult decision to cull a phase 3 study of Verzenio in HER2-positive early breast cancer, Dan Skovronsky, M.D., Ph.D., chief scientific and medical officer at Lilly, said on a call with investors Thursday.

Details were slim, but Skovronsky blamed the decision on changes in the treatment landscape plus global enrollment challenges.

Importantly, this decision does not change our commitment to an investment in breast cancer, Lillys chief scientist said.

News of the Verzenio trial halt comes a week after Lilly announced it was pulling the plug on Olumiants development in lupus. Separately, Olumiants application in moderate-to-severe atopic dermatitis could be in jeopardy, thanks to a stalemate with the FDA about the exact patient population, the company said last week. Lilly expects regulatory action on Olumiants eczema bid very soon, Skovronsky said Thursday.

RELATED:CMS' Biogen decision could spell problems for Lilly, Roche Alzheimer's drugs, half of surveyed neurologists say

During the call,Lilly shed more light on Olumiants regulatory impasse in eczema. Lilly believes Olumiant benefits eczema patients most when used in early treatment, Patrik Jonsson, SVP and president of Lilly immunology and president of Lilly USA, said on the call. The FDA, conversely, currently has the position of saving Olumiant for the refractory patients, where we see the incremental value of Olumiant to be quite limited.

If that doesnt change, a complete response letter is likely, Jonsson said.

Lilly has also submitted Olumiant for approval in alopecia, though ananalyst on Wednesdays call questioned whether safety concerns around the JAK-inhibitor class at large could blunt the drugs ambitions there. Lilly simply said it was encouraged by the data its seen so far, and it highlighted the immense opportunity in the disease.

There are currently no treatments approved for alopecia areata, Jonsson said. We have the opportunity here to be first in disease with Olumiant.

There are about 360,000 patients diagnosed with alopecia in the U.S., some 100,000 of whom would be eligible for treatment with a JAK inhibitor, Jonsson added.

RELATED:UPDATED: Eli Lilly to plow a total of $1.5B into 2 new manufacturing plants

For the fourth quarter, Eli Lillys revenue jumped 8% to $7.9 billion. Excluding COVID-19 antibodies, sales for the last three months of the year climbed 6%. Full-year sales increased 15% to $28.3 billion or 10% after subtracting Lillys pandemic antibodies from the equation.

Last month, The FDAtweakedits emergency nod for Lilly and Regenerons monoclonal antibodies, citing recent data showing the drugs arent effective against omicron. The antibodies are now limited to patients whove been infected with or exposed to a variant susceptible to the therapies.

Lilly snared $1.1 billion in COVID-19 antibody revenue for the fourth quarter. Lilly says it delivered roughly 435,000 doses out of 614,000 in the last three months of the year, with most of the remaining doses already shipped out last month.

Lilly credited its fourth-quarter momentum to growth drugs like Trulicity, Taltz, Verzenio, Olumiant, Emgality and more.

"Lillys margin profile represents one of the strongest expansion stories in Pharma, in our opinion, with the potential for mid-teens EPS growth, Cantor Fitzgerald analyst Louise Chen wrote in a note to clients Thursday. Her team thinks Lilly is poised to enter a growth period through 2030, helped by multiple readouts for products like donanemab in Alzheimers disease and tirzepatide in Type 2 diabetes.

Lilly has forecasted full-year 2022 sales between $27.8 billion and $28.3 billion.

View post:
Eli Lilly nixes Verzenio's phase 3 HER2-positive early breast cancer trial - FiercePharma

LEO Pharma announced new 16-week data on tralokinumab-ldrm, stating that it led to significant improvements in itch, sleep interference, anxiety and depression, and overall quality of life among adolescents aged 12-17 years old with moderate-to-severe atopic dermatitis.

The data were presented at the Western Society of Allergy, Asthma & Immunology (WSAAI) 59th Annual Scientific Session in Maui.

Tralokinumab-ldrm was previously approved by the US Food and Drugs Administration (FDA) in December 2021 for the treatment of adults with moderate-to-severe atopic dermatitis. It is the first and only FDA approved biologic that binds to and inhibits the interleukin (IL)-13 cytokine.

The most recent analysis evaluated patient-reported outcomes with the biologic compared to placebo at week 16 during the 52-week monotherapy phase 3 ECZTRA 6 trial.

A total of 100 patients received 150 mg of tralokinumab-ldrm, while 101 received 300 mg of the biologic. Investigators observed that siginificantly more adolescent patients achieved improvements with the biologic every 2 weeks compared to the 100 patients who received placebo.

A 4-point improvement in adolescent Worst Daily Pruritus Numeric Rating Scale (NRS) was seen in 23.2% of patients receiving tralokinumab-ldrm 150 mg (P<0.001), 25.0% of those in the tralokinumab-ldrm 300 mg group (P<0.001), and 3.3% placebo, while a 6-point improvement in Childrens Dermatology Life Quality Index (CDLQI) was recorded in 31.0% of patients receiving tralokinumab-ldrm 150 mg (P=0.029), 39.5% tralokinumab-ldrm 300 mg (P<0.001), and 15.9% placebo.

Additionally, a 6-point improvement in Patient Oriented Eczema Measure (POEM) was reported in 38.7% of the tralokinumab-ldrm 150 mg group (P<0.001), 46.8% of the tralokinumab-ldrm 300 mg group, (P<0.001), and 10.5% of the placebo group. The biologic was also associated with greater improvement than placebo in eczema-related sleep NRS.

Currently, Tralokinumab-lfrm is not FDA approved in adolescents, and its efficacy and safety have not been full evaluated.

Read more here:
Tralokinumab Linked to Overall Quality of Life Improvements in Adolescents with AD - MD Magazine

Heavy rain South Island moves to the North Island Sunday

Its all about the rain, the South Island in particular the West Coast sees heavy rain today and Friday, inland Canterbury may actually see some heavy rain into the second half of Friday before starting to ease overnight. Heavy rain moves to the upper South Island (Tasman, Nelson and perhaps Marlborough) on Saturday then heavy rain potential shifts to the North Island on Sunday and continues there early next week. There is still room for change here so not everything is set in stone just yet. More at this link here.

High humidity and rain potential may bring facial eczema

With the dry weather we have had for the North Island lately and now high humidity plus the potential for high amounts of rain coming up this leads to the potential for facial eczema in livestock. Something to take note of.

Relief is coming in the south

Relief from hot temperatures is starting to move in today for the South Island with southerly winds. The lower South Island will notice this today, the upper South Island tomorrow. The North Island remains very hot then starts to see some relief later into Sunday and Monday.

Continue reading here:
Weather Headlines for Thursday (x3): The path of the heavy rain, Facial Eczema? Cooler southerlies in the south - WeatherWatch.co.nz

A body-positive influencer shut down an Instagram troll who wrongly criticised her weight.

Australian model and bikini designer Karina (@karinairby) often posts uplifting content to her 1.2 million followers to encourage women to appreciate their bodies, no matter the size or shape.

On Sunday, the 29-year-old took to the platform to hit back at a troll who called her "obese" and "disgusting."

Putting them on blast, Karina launched into the perfect response to "publicly attempt to educate [them] on the female body!"

"Clearly youve had one too many in counters with blow-up dolls and watched a little too much pretty porn and its warped perception," she said [sic].

"Buckle up buttercup. Youre in for a rude shock!

Sign up to our free Indy100 weekly newsletter

"This is not repulsive and very far from obese. Yeah, I may have cellulite, eczema and some meat on my bones. But Im a young healthy female that you could be so lucky to have a chance with."

"99.9% of women dont look like a Barbie doll.

"99.9% of women have cellulite, lumps, dumps, scars, stretch marks, muscle and skin.

"99.9% of women would never date you because of your repulsive outlook on what a female should look like.

Karina continued: "And as for people supporting what I stand for (body positivity and acceptance).

"Perhaps if more people where being themselves online and companies shared and marketed different body types youd be better educated by now.

"Im glad we got to have this chat."

Overnight, the Instagram post racked almost 30,000 likes and hundreds of comments praising the influencer for stepping up and shutting them down.

"Honestly how dare they use a reference from the office as their name, only to spew blasphemy against our goddess," one joked.

Another added: "Youre sper brave! Youre an inspiration! Youre WOMAN!"

While one said they "always applaud your response to these."

Indy100 reached out to Karina for comment.

Have your say in our news democracy. Click the upvote icon at the top of the page to help raise this article through the indy100 rankings.

Link:
Influencer has perfect response to troll who called her 'obese' and 'disgusting' - indy100